Skip to main content
Top

Pathology & Oncology Research

Issue 3/2001

Content (10 Articles)

Article

Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry

Francisco J. Esteva, Gabriel N. Hortobagyi, Aysegul A. Sahin, Terry L. Smith, Dot Mon Chin, Shang -Ying Liang, Lajos Pusztai, Aman U. Buzdar, Sarah S. Bacus

Article

Immunohistochemical assessment and prognostic value of hepatitis B virus X protein in chronic hepatitis and primary hepatocellular carcinomas usinganti-HBxAg monoclonal antibody

József Pál, Csilla Somogyi, Ágnes Szmolenszky, György Szekeres, József Sípos, Géza Hegedüs, Ilona Martzinovits, János Molnár, Péter Németh

Article

Vascularization pattern of c6 glioma is modified with medroxyprogesterone acetate and ibuprofen in Wistar rat brain

Meric A. Altinoz, Engin Ozar, Murat Taskin, Evin Bozcali, Ayhan Bilir, Tuncay Altug, Adnan Aydiner, Aydin Sav

Article

Significance of immunohistochemical c-ErbB-2 product localisation pattern for prognosis in human breast cancer

Syed Abdus Aziz, Shahid Pervez, Shaista Khan, Naila Kayani, Syed Igbal Azam, Mohammed Hussain Rahbar

Article

Alterations in MDM2 expression in esophageal squamous cell carcinoma: Relationship with p53 status

Sonia Arora, Robin Mathew, Meera Mathur, Tushar Kant Chattopadhayay, Ranju Ralhan

Article

Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer

Semra Karaburun Paker, Bahar Kilicarslan, Akif M. C. Ýftcýoglu, Sevim Oztekin, Figen C. Sargin, Tibet Erdogru, Mehmet Baykara

Article

Proliferating activity in differential diagnosis of benign phyllodes tumor and cellular fibroadenomas: Is it helpful?

Resmiye Kaya, Hadice Elif Pesterelý, Gülgün Erdogan, Kemal Hakan Gülkesen, Seyda Karavelý

Seminar

Molecular pathology of tumor metastasis

József Tímár, Orsolya Csuka, Zsolt Orosz, András Jeney, László Kopper

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine